search
Back to results

Lifestyle Intervention and Metformin for Women With Polycystic Ovary Syndrome (PCOS)

Primary Purpose

Polycystic Ovary Syndrome

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Metformin
Placebo
Lifestyle Intervention
Sponsored by
Milton S. Hershey Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Polycystic Ovary Syndrome focused on measuring Polycystic Ovary Syndrome (PCOS), Anovulation, Elevated Testosterone

Eligibility Criteria

12 Years - 39 Years (Child, Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria: Spontaneous intermenstrual periods of greater than or equal to 45 days or a total of 8 or less periods per year Elevated testosterone levels General good health Off of current medications which may confound response to study medications Exclusion Criteria: Pregnancy Lactose Intolerance Medical Contraindications Elevated Prolactin, 17hydroxyprogesterone, or Follicle stimulating hormone blood tests Diabetes, liver, heart, kidney or uncorrected thyroid disease

Sites / Locations

  • Penn State Milton S. Hershey Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Metformin

Placebo

Arm Description

Metformin

Placebo

Outcomes

Primary Outcome Measures

Change in Testosterone After 6 Months of Treatment

Secondary Outcome Measures

Ovulation Rate
Count of ovulations per subject during the treatment period.
Change in Insulin Sensitivity Index After 6 Months of Treatment

Full Information

First Posted
September 8, 2005
Last Updated
March 19, 2018
Sponsor
Milton S. Hershey Medical Center
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
search

1. Study Identification

Unique Protocol Identification Number
NCT00151411
Brief Title
Lifestyle Intervention and Metformin for Women With Polycystic Ovary Syndrome (PCOS)
Official Title
The Effect of Combination Therapy With Lifestyle Intervention and Metformin in Females With Polycystic Ovary Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
March 2018
Overall Recruitment Status
Completed
Study Start Date
October 2004 (undefined)
Primary Completion Date
March 2008 (Actual)
Study Completion Date
March 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Milton S. Hershey Medical Center
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine if the combination therapy of lifestyle intervention and use of Metformin together will improve ovulation induction and hyperandrogenemia in women with polycystic ovary syndrome, by gathering data from adult and adolescent females.
Detailed Description
PCOS is characterized by excess circulating androgen levels and chronic anovulation. PCOS is also characterized by insulin resistance and hyperinsulinemia. Several recent studies in a variety of non-hospital based populations have provided evidence that the incidence of hyperandrogenic chronic anovulation is in the range of 4-6% of the female population. Improvements in insulin sensitivity in women with PCOS, either through lifestyle changes or through pharmaceutical intervention, have consistently resulted in a marked improvement in the reproductive and metabolic abnormalities in PCOS. The primary objective in the adult female population is to determine that combination therapy will improve ovulatory frequency. Secondary objective is to improve circulating hyperandrogenemia and insulin sensitivity then single agent therapy. The primary objective of the adolescent population is to determine that the combination therapy will improve hyperandrogenemia. Secondary objective is to improve ovulatory frequency and insulin sensitivity than just the use of a single agent therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Polycystic Ovary Syndrome
Keywords
Polycystic Ovary Syndrome (PCOS), Anovulation, Elevated Testosterone

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
114 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Metformin
Arm Type
Experimental
Arm Description
Metformin
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Drug
Intervention Name(s)
Metformin
Intervention Description
Medication was initiated in a step-up fashion every five days, from one tablet per day to four (500 mg per tablet).
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo
Intervention Type
Behavioral
Intervention Name(s)
Lifestyle Intervention
Intervention Description
A combined intervention of diet and exercise was employed with the goal of achieving an average weight loss of at least 7% of initial body weight over six months with a prescription of 150 min/week of exercise combined with a low-calorie diet.
Primary Outcome Measure Information:
Title
Change in Testosterone After 6 Months of Treatment
Time Frame
baseline and 6 months
Secondary Outcome Measure Information:
Title
Ovulation Rate
Description
Count of ovulations per subject during the treatment period.
Time Frame
6 months
Title
Change in Insulin Sensitivity Index After 6 Months of Treatment
Time Frame
baseline and 6 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
39 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Spontaneous intermenstrual periods of greater than or equal to 45 days or a total of 8 or less periods per year Elevated testosterone levels General good health Off of current medications which may confound response to study medications Exclusion Criteria: Pregnancy Lactose Intolerance Medical Contraindications Elevated Prolactin, 17hydroxyprogesterone, or Follicle stimulating hormone blood tests Diabetes, liver, heart, kidney or uncorrected thyroid disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard Legro, M.D.
Organizational Affiliation
Milton S. Hershey Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Penn State Milton S. Hershey Medical Center
City
Hershey
State/Province
Pennsylvania
ZIP/Postal Code
17033
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
21704212
Citation
Ladson G, Dodson WC, Sweet SD, Archibong AE, Kunselman AR, Demers LM, Lee PA, Williams NI, Coney P, Legro RS. Effects of metformin in adolescents with polycystic ovary syndrome undertaking lifestyle therapy: a pilot randomized double-blind study. Fertil Steril. 2011 Jun 30;95(8):2595-8.e1-6. doi: 10.1016/j.fertnstert.2011.05.048.
Results Reference
derived
PubMed Identifier
21193187
Citation
Ladson G, Dodson WC, Sweet SD, Archibong AE, Kunselman AR, Demers LM, Williams NI, Coney P, Legro RS. The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. Fertil Steril. 2011 Mar 1;95(3):1059-66.e1-7. doi: 10.1016/j.fertnstert.2010.12.002. Epub 2010 Dec 30.
Results Reference
derived
Links:
URL
http://www.pennstatehershey.org/web/obgyn/patientcare/clinicaltrials
Description
Click here for more information about this study

Learn more about this trial

Lifestyle Intervention and Metformin for Women With Polycystic Ovary Syndrome (PCOS)

We'll reach out to this number within 24 hrs